
1. ann neurol. 1988;23 suppl:s82-7.

long-term administration 3'-azido-2',3'-dideoxythymidine patients with
aids-related neurological disease.

yarchoan r(1), thomas rv, grafman j, wichman a, dalakas m, mcatee n, berg g,
fischl m, perno cf, klecker rw, et al.

author information: 
(1)national cancer institute, bethesda, md 20892.

3'-azido-2',3'-dideoxythymidine (azt) administered 7 patients with
human immunodeficiency virus-associated neurological disease: 3 dementia, 2 
with peripheral neuropathy, 1 dementia peripheral neuropathy, 1 with
t-10 paraplegia. six patients showed improvement neurological
dysfunction administered azt, assessed clinical evaluation,
neuropsychological testing, nerve conduction studies, and/or positron emission
tomographic scans. three 6 patients showed sustained improvement 5 18
months initiation azt therapy. results suggest certain
human immunodeficiency virus-associated neurological abnormalities least
partially reversible following administration antiretroviral therapy and
provide rationale studies using antiretroviral chemotherapy.

doi: 10.1002/ana.410230722 
pmid: 2831806  [indexed medline]

